



**Lucemyra (lofexidine)**  
Effective 08/01/2019

<b>Plan</b>	<input checked="" type="checkbox"/> MassHealth <input type="checkbox"/> Commercial/Exchange	<b>Program Type</b>	<input checked="" type="checkbox"/> Prior Authorization
<b>Benefit</b>	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		<input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
<b>Specialty Limitations</b>	N/A		
<b>Contact Information</b>	<b>Specialty Medications</b>		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	<b>Non-Specialty Medications</b>		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	<b>Medical Specialty Medications (NLX)</b>		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
<b>Exceptions</b>	N/A		

**Overview**

Lucemyra (lofexidine) is a central alpha-2 adrenergic agonist used to mitigate opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.

**Coverage Guidelines**

Must meet all the following and documentation is submitted

1. Medication is being used to facilitate abrupt opioid discontinuation
2. Member is at least 18 years of age
3. Member has had an adverse reaction or inadequate response or a contraindication to oral clonidine
4. Opioid medications have been discontinued
5. Requested duration of therapy is 14 days or less

**Continuation of Therapy**

Reauthorization may be granted intervals when all the following criteria have been met:

1. Physician assessment is provided documenting member’s clinical response
2. Member has not filled opioid medications
3. Physician is titrating dose down based on member’s response.

**Limitations**

1. Approvals will be granted for 14 days
2. The following quantity limits apply:

Lucemyra	0.72mg (4x0.18mg tablets) four times a day
----------	--



	If Lucemyra was initiated in an inpatient setting, the total course of therapy should not exceed 14 days.
--	---

### References

1. Lucemyra (lofexidine) [prescribing information]. Louisville, KY: US WorldMeds, LLC; September 2020
2. Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) National Practice Guideline for the use of medications in the treatment of addiction involving opioid use. *J Addict Med.* 2015;9(5):358-367. doi: 10.1097/ADM.000000000000166
3. Akhurst JS. Lofexidine in opiate withdrawal: a safety and usage survey. *Pharmacoepidemiol Drug Saf.* 2000;9(1):43-47
4. Catapres (clonidine hydrochloride) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; August 2016
5. Sevarino K. Medically supervised opioid withdrawal during treatment for addiction. Post TW, ed. *UpToDate.* Waltham, MA: UpToDate Inc. <http://www.uptodate.com>. Accessed December 21, 2017
6. Gowing L, Farrell M, Ali R, White JM. Alpha<sub>2</sub>-adrenergic agonists for the management of opioid withdrawal. *Cochrane Database Syst Rev.* 2016;3;(5):CD002024. doi: 10.1002/14651858

### Review History

04/17/18 – Reviewed

08/01/19 – Implemented

09/22/2021- Reviewed Sept P&T; references updated no clinical changes

### Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.